The inhibition of HDAC2 expression promotes histone acetylation in the MIR22HG promoter region, thereby up-regulating MIR22HG expression and promoting the production of miR-22-5p, ultimately increasing the sensitivity of liver cancer radiotherapy. Here, HDAC2 is linked to liver cancer.